2 weeks Ago By ABMN Staff
Immunocore Holdings plc ( NASDAQ:IMCR – Get Free Report ) has been given a consensus rating of “Moderate Buy” by the twelve research firms that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and eleven have issued a buy recommendation on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $80.
40. Several analysts have weighed in on the stock. Oppenheimer reissued an “outperform” rating and set a $89.
00 target price (up previously from $87.00) on shares of Immunocore in a research report on Friday, August 9th. Cantor Fitzgerald restated an “overweight” rating on shares of Immunocore in a research note on Monday, September 9th.
JPMorgan Chase & Co. lowered their price target on Immunocore from $70.00 to $66.
00 and set an “overweight” rating for the company in a research report on Wednesday, July 10th. Needham & Company LLC cut their price objective on Immunocore from $81.00 to $78.
00 and set a “buy” rating on the stock in a report on Tuesday, September 17th. Finally, Barclays decreased their target price on Immunocore from $92.00 to $66.
00 and set an “overweight” rating for the company in a report on Friday, August 9th. View Our Latest Stock Analysis on Immunocore Institutional Trading of Immunocore Immunocore Stock Performance Shares of Immunocore stock opened at $31.40 on Friday.
Immunocore has a 52 week low of $29.76 and a 52 week high of $76.98.
The company has a market capitalization of $1.57 billion, a PE ratio of -25.74 and a beta of 0.
73. The stock’s fifty day moving average is $35.94 and its two-hundred day moving average is $45.
16. The company has a quick ratio of 5.15, a current ratio of 5.
17 and a debt-to-equity ratio of 1.31. Immunocore ( NASDAQ:IMCR – Get Free Report ) last announced its quarterly earnings results on Thursday, August 8th.
The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.
25. Immunocore had a negative return on equity of 14.68% and a negative net margin of 19.
16%. The firm had revenue of $75.40 million for the quarter, compared to analyst estimates of $74.
58 million. During the same quarter last year, the firm posted ($0.37) earnings per share.
The business’s revenue for the quarter was up 26.2% on a year-over-year basis. As a group, analysts expect that Immunocore will post -1.
79 earnings per share for the current year. Immunocore Company Profile ( Get Free Report Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma.
It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. Featured Stories Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter .
.
